SCHEMBL723440

SCHEMBL723440

COc1ccc(CNc2ncnc3[nH]cnc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.59
CCNB2 O95067 2/20 0.59
CCNB1 P14635 2/20 0.59
CCNB3 Q8WWL7 2/20 0.59
EGFR P00533 4/20 0.55
POLB P06746 2/20 0.55
NR2F2 P24468 1/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 2/20 0.54
MAPK1 P28482 1/20 0.54
OXTR P30559 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PDE5A O76074 1/20 0.53
BLM P54132 1/20 0.52
AURKA O14965 1/20 0.52
RPS6KB1 P23443 1/20 0.52
THRB P10828 2/20 0.51
HTT P42858 1/20 0.51
PRMT1 Q99873 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4921526 0.88 SMN1; SMN2 (0.53) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL4914359 0.86 MAPT (0.51) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL4922889 0.86 CCNB2 (0.45) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL4922847 0.86 CCNB2 (0.45) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL17815679 0.85 MAPT (0.67) CDK1CCNB2CCNB1CCNB3MAPT
SCHEMBL30850525 0.85 HTT (0.58) CDK1EGFRMAPTMAPK1MEN1
SCHEMBL1443197 0.85 HTT (0.58) CDK1EGFRMAPTMAPK1MEN1
SCHEMBL723525 0.85 PRMT1 (0.64) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL4920961 0.85 PRMT1 (0.50) CDK1CCNB2CCNB1CCNB3EGFR
SCHEMBL4937104 0.84 CCNB2 (0.43) CDK1CCNB2CCNB1CCNB3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1671616-B1 Hair growth promoter composition LION CORP (JP) 2012-02-29 EP claimed
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) 2005-02-24 US claimed
EP-1419157-A2 HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2004-05-19 EP claimed
WO-2003040144-A2 HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-05-15 WO claimed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
WO-2023078482-A1 HETEROCYCLIC PURINE CYTOKININ DERIVATIVES, THEIR USE IN WOUND HEALING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES Univerzita Palackého v Olomouci (CZ) 2023-05-11 WO disclosed
EP-4115882-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING The General Hospital Corporation (US) 2023-01-11 EP disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20070116657-A1 Hair growth promotor composition LION CORPORATION (JP) 2007-05-24 US disclosed
US-20070116657-A1 Hair growth promotor composition LION CORPORATION (JP) 2007-05-24 US disclosed
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) 2005-02-24 US disclosed
EP-1419157-A2 HETEROCYCLIC COMPOUND BASED ON N sp 6 /sp −SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2004-05-19 EP disclosed
WO-2003040144-A2 HETEROCYCLIC COMPOUND BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-05-15 WO disclosed
EP-0540854-B1 Preparation for promoting hair growth SANSHO SEIYAKU KK (JP) 1998-01-21 EP disclosed
US-5656264-A ADMINISTERING TO THE SCALP OF THE MALE A PREPERATION CONSITING OF 6-BENZYLAMINOPURINE SANSYO SEIYAKU CO., LTD. (JP) 1997-08-12 US disclosed
EP-0540854-A2 Preparation for promoting hair growth Sansho Seiyaku Co., Ltd. (JP) 1993-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK1 3620/4885CCNB2 4151/4885CCNB1 4150/4885
US-20070116657-A1 Hair growth promotor composition BCOR, SPOUT1, IL36G CDK1 2584/4885CCNB2 855/4885CCNB1 711/4885
US-20050043328-A1 Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds ATIC, UMPS, CCNB1 CDK1 35/4885CCNB2 19/4885CCNB1 3/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK1 3620/4885CCNB2 4151/4885CCNB1 4150/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 CDK1 3620/4885CCNB2 4151/4885CCNB1 4150/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 CDK1 3620/4885CCNB2 4151/4885CCNB1 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.